Michael J. Whalen, MD

George Washington University School of Medicine & Health Science

Michael J. Whalen, MD is Assistant Professor of Urology at the George Washington University School of Medicine & Health Science. He received his medical degree from Columbia College of Physicians & Surgeons in New York City. He completed his residency in Urology at New York Presbyterian Hospital-Columbia University Medical Center. Dr. Whalen has received fellowship training in Robotic and Minimally Invasive Urologic Oncology at Mount Sinai Hospital in New York and a completed a second fellowship in Urologic Oncology at Yale-New Haven Hospital.
Dr. Whalen’s specialty focus involves treatment of urological cancers, with expertise in both major open and minimally invasive surgery. His clinical interests include prostate cancer (including prostate MRI, MRI-ultrasound fusion biopsy and cryotherapy), bladder cancer (including blue-light cystoscopy and continent/incontinent urinary diversion), kidney cancer, testis cancer, adrenal cancer, ureteral cancer, robotic surgery with the DaVinci system (including prostatectomy, cystectomy, partial nephrectomy, and adrenalectomy) and laparoscopic surgery.
Dr. Whalen is actively involved in clinical outcomes research focusing on cancer of the prostate, bladder, and kidneys. He has published numerous original research articles in peer-reviewed journals, including Urologic Oncology, Urology Practice, Prostate, and BJU International. His research interests include robotic surgery techniques, optimization of pathologic reporting of urological cancers, and multiparametric magnetic resonance imaging (mp-MRI) and its role in prostate cancer management—active surveillance, post-treatment biochemical recurrence, and comparison to/integration with commercially-available serum-based and tissue-based genomic assays.
Dr. Whalen has presented at numerous conferences in the US and internationally, including the AUA, the AUA New York Section Ferdinand C. Valentine Medal & Resident Essay Meeting, the 2016 World Cancer Congress in Shanghai, China, and the 2014 AUA National Chief’s Debate. He is a member of the American Urological Association and serves as a reviewer for Current Urology, and as a reviewer/statistical consultant for the Journal of Urology.

Disclosure information not submitted.

Presentation(s):

• MP12: Kidney Cancer: Advanced (including Drug Therapy) I

  Friday, May 13, 2022
  1:00 PM – 2:15 PM